Paul
03-29-2004, 06:45 AM
CombinatoRx Incorporated a privately held biopharmaceutical company creating novel combination medicines today announced that it will present data on CRx-026 its lead oncology product candidate at the 2004 Annual Meeting of the American Association of Cancer Research (AACR) being held this week in Orlando Florida. CRx-026 is a dual action anti-cancer agent that was discovered through the CombinatoRx proprietary platform: combination high throughput screening (cHTS(TM)) of millions of combinations.
The presentation will describe the novel mechanism of action of CRx-026 which achieves a synergistic anti-cancer effect through the coordinated inhibition of the mitotic kinesin hsEg5/KSP and the PRL phosphatases. CombinatoRx has integrated the components of CRx-026 into a pharmaceutical composition and has advanced this novel anti-cancer agent into clinical studies.
"In cancer hitting one target isn't enough. The dual action of CRx-026 represents an exciting multi-targeted approach to treating cancer " commented Curtis Keith Ph.D. VP Research at CombinatoRx. "Based on the therapeutic potential of this important novel mechanism we have initiated a Phase I/II clinical program with CRx-026 in patients with solid tumors and advanced metastatic disease " added Jan Lessem M.D. Ph.D. Chief Medical Officer at CombinatoRx
The presentation will describe the novel mechanism of action of CRx-026 which achieves a synergistic anti-cancer effect through the coordinated inhibition of the mitotic kinesin hsEg5/KSP and the PRL phosphatases. CombinatoRx has integrated the components of CRx-026 into a pharmaceutical composition and has advanced this novel anti-cancer agent into clinical studies.
"In cancer hitting one target isn't enough. The dual action of CRx-026 represents an exciting multi-targeted approach to treating cancer " commented Curtis Keith Ph.D. VP Research at CombinatoRx. "Based on the therapeutic potential of this important novel mechanism we have initiated a Phase I/II clinical program with CRx-026 in patients with solid tumors and advanced metastatic disease " added Jan Lessem M.D. Ph.D. Chief Medical Officer at CombinatoRx